Use of Haploidentical Stem Cell Transplantation Continues to Increase: the 2015 European Society for Blood and Marrow Transplant Activity Survey Report

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2017 Mar 14

PMID 28287639

Citations 122

Authors

J R Passweg

H Baldomero

P Bader

C Bonini

R F Duarte

C Dufour

A Gennery

N Kroger

J Kuball

F Lanza

S Montoto

A Nagler

J A Snowden

J Styczynski

M Mohty

Affiliations

Soon will be listed here.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25%; 96% allogeneic), lymphoid malignancies 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005. Growth is seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.

Citing Articles

NFAT single-deficient murine T cells reduce the risk of aGvHD while controlling cytomegalovirus infection.

Hundhausen N, Majumder S, Xiao Y, Haeusl S, Goehler H, Seal R iScience. 2025; 28(2):111937.

PMID: 40028277 PMC: 11872454. DOI: 10.1016/j.isci.2025.111937.

Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.

Zhang A, Huang Z, Zhang R, Wei R, Jiang S, Chen H Br J Haematol. 2024; 206(2):615-627.

PMID: 39710371 PMC: 11829143. DOI: 10.1111/bjh.19958.

Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT.

Passweg J, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A Bone Marrow Transplant. 2024; 60(2):227-236.

PMID: 39578528 PMC: 11810786. DOI: 10.1038/s41409-024-02459-0.

Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.

Benoit T, Bachofner A, Wolfensberger N, Zaugg-Berger Y, Manz M, Schneidawind D Eur J Haematol. 2024; 114(2):315-324.

PMID: 39501442 PMC: 11707813. DOI: 10.1111/ejh.14340.

Factors influencing unrelated stem cell donation a mixed-methods integrated systematic review.

Forbes J, Rice P, Groarke J, Berry E, Graham H, Graham-Wisener L Br J Health Psychol. 2024; 30(1):e12758.

PMID: 39449116 PMC: 11586825. DOI: 10.1111/bjhp.12758.

References

Gratwohl A, Baldomero H, Aljurf M, Pasquini M, Bouzas L, Yoshimi A . Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303(16):1617-24. PMC: 3219875. DOI: 10.1001/jama.2010.491. View

Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P . Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2016; 52(2):191-196. DOI: 10.1038/bmt.2016.258. View

Appelbaum F . Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357(15):1472-5. DOI: 10.1056/NEJMp078166. View

Tolar J, Le Blanc K, Keating A, Blazar B . Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010; 28(8):1446-55. PMC: 3638893. DOI: 10.1002/stem.459. View

Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P . Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016; 51(6):786-92. PMC: 4895175. DOI: 10.1038/bmt.2016.20. View

Bonini C, Mondino A . Adoptive T-cell therapy for cancer: The era of engineered T cells. Eur J Immunol. 2015; 45(9):2457-69. DOI: 10.1002/eji.201545552. View

Gratwohl A, Schwendener A, Baldomero H, Gratwohl M, Apperley J, Niederwieser D . Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica. 2010; 95(4):637-43. PMC: 2857194. DOI: 10.3324/haematol.2009.015586. View

Gratwohl A . Bone marrow transplantation activity in Europe 1990. European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant. 1991; 8(3):197-201. View

Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G . Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2009; 45(2):219-34. DOI: 10.1038/bmt.2009.141. View

10.

Copelan E . Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813-26. DOI: 10.1056/NEJMra052638. View

11.

Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K . The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant. 2009; 43(4):275-91. DOI: 10.1038/bmt.2009.7. View

12.

Passweg J, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P . The EBMT activity survey: 1990-2010. Bone Marrow Transplant. 2012; 47(7):906-23. DOI: 10.1038/bmt.2012.66. View

13.

Jeyakumar D, OBrien S . The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia. Oncology (Williston Park). 2016; 30(11):1008-15. View

14.

Brunstein C, Fuchs E, Carter S, Karanes C, Costa L, Wu J . Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118(2):282-8. PMC: 3138683. DOI: 10.1182/blood-2011-03-344853. View

15.

Gratwohl A, Pasquini M, Aljurf M, Atsuta Y, Baldomero H, Foeken L . One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015; 2(3):e91-100. DOI: 10.1016/S2352-3026(15)00028-9. View

16.

Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Apperley J, Frauendorfer K . The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant. 2010; 46(2):174-91. DOI: 10.1038/bmt.2010.69. View

17.

Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A . Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002; 100(7):2374-86. DOI: 10.1182/blood-2002-03-0675. View

18.

Passweg J, Baldomero H, Peters C, Gaspar H, Cesaro S, Dreger P . Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014; 49(6):744-50. PMC: 4051369. DOI: 10.1038/bmt.2014.55. View

19.

Luznik L, ODonnell P, Symons H, Chen A, Leffell M, Zahurak M . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-50. PMC: 2633246. DOI: 10.1016/j.bbmt.2008.03.005. View

20.

Foeken L, Green A, Hurley C, Marry E, Wiegand T, Oudshoorn M . Monitoring the international use of unrelated donors for transplantation: the WMDA annual reports. Bone Marrow Transplant. 2010; 45(5):811-8. DOI: 10.1038/bmt.2010.9. View